COST-EFFECTIVENESS ANALYSIS OF OCTREOTIDE LAR VERSUS LANREOTIDE SR FOR THE POSTOPERATIVE TREATMENT OF PATIENTS WITH ACTIVE ACROMEGALY IN CHINA

Author(s)

Xuan J1, Zhang Z2, Wang Y2, Mao Z3, Lu YJ4, Wang R5
1Sun Yat-Sen University, Guangzhou, China, 2Huashan Hospital of Fudan University, Shanghai, China, 3The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China, 4Shanghai Centennial Scientific Co.,Ltd, Shanghai, China, 5Peking Union Medical College Hospital, Beijing, China

Conference/Value in Health Info

2016-05, ISPOR 2016, Washington DC, USA

Value in Health, Vol. 19, No. 3 (May 2016)

Code

PSY42

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Rare and Orphan Diseases

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×